|Videos|June 30, 2014
An Analysis of SARC021
Author(s)Brian A. Van Tine, MD, PhD
Brian A. Van Tine, MD, PhD, assistant professor, Washington University School of Medicine in St. Louis, discusses the SARC021 trial, which examined TH-302 in combination with doxorubicin versus doxorubicin alone to treat patients with locally advanced unresectable or metastatic soft tissue sarcoma.
Advertisement
Brian A. Van Tine, MD, PhD, assistant professor, Washington University School of Medicine in St. Louis, discusses the SARC021 trial, which examined TH-302 in combination with doxorubicin versus doxorubicin alone to treat patients with locally advanced unresectable or metastatic soft tissue sarcoma.
Clinical Pearls:
- TH-302 is a hypoxia-released ifosfamide that has none of the side effects found in traditional ifosfamides.
- TH-302 appears to be well tolerated and provide patients with a better quality of life.
- Data from this trial have the potential to change the standard of care in sarcoma, Van Tine says.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Iberdomide, the First CELMoD for Relapsed/Refractory Multiple Myeloma
2
With 4 Guideline-Preferred Options, CNS Activity Is Deciding Frontline ROS1+ NSCLC Therapy
3
FDA Grants Breakthrough Device Designation to Blood-Based Lung Cancer Screening
4
Zipalertinib Combo Meets PFS End Point in First-Line EGFR Exon 20+ NSCLC
5